Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?
Files
Publication date
2015-03
Authors
Lankester, Arjan C.
Locatelli, Franco
Bader, Peter
Rettinger, Eva
Egeler, Maarten
Katewa, Satyendra
Pulsipher, Michael A.
Nierkens, Stefan
Schultz, Kirk
Handgretinger, Rupert
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
Although allogeneic hematopoietic stem cell transplantation (HSCT) is a curative approach for many pediatric patients with hematologic malignancies and some nonmalignant disorders, some critical obstacles remain to be overcome, including relapse, engraftment failure, graft-versus-host disease (GVHD), and infection. Harnessing the immune system to induce a graft-versus-tumor effect or rapidly restore antiviral immunity through the use of donor lymphocyte infusion (DLI) has been remarkably successful in some settings. Unfortunately, however, the responses to DLI can be variable, and GVHD is common. Thus, manipulations to minimize GVHD while restoring antiviral immunity and enhancing the graft-versus-tumor effect are needed to improve outcomes after allogeneic HSCT. Cellular therapies, defined as treatment modalities in which hematopoietic or nonhematopoietic cells are used as therapeutic agents, offer this promise for improving outcomes post-HSCT. This review presents an overview of the field for pediatric cell therapies in the transplant setting and discusses how we can broaden applicability beyond phase I. (C) 2015 American Society for Blood and Marrow Transplantation.
Keywords
Adoptive cellular therapy, Pediatrics, Stem cell transplantation, Chimeric antigen receptor, CHIMERIC ANTIGEN RECEPTOR, VERSUS-HOST-DISEASE, NATURAL-KILLER-CELLS, ACUTE MYELOID-LEUKEMIA, T-REGULATORY CELLS, BONE-MARROW-TRANSPLANTATION, MESENCHYMAL STROMAL CELLS, MINOR HISTOCOMPATIBILITY ANTIGENS, ACUTE LYMPHOBLASTIC-LEUKEMIA, ALLOGENEIC-DENDRITIC CELLS, Transplantation, Hematology, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
Citation
Lankester, A C, Locatelli, F, Bader, P, Rettinger, E, Egeler, M, Katewa, S, Pulsipher, M A, Nierkens, S, Schultz, K, Handgretinger, R, Grupp, S A, Boelens, J J, Bollard, C M & Westhafen Intercontinental Grp 2015, 'Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?', Biology of Blood and Marrow Transplantation, vol. 21, no. 3, pp. 402-411. https://doi.org/10.1016/j.bbmt.2014.07.018